Epidemiology of Non-Alcoholic Fatty Liver Disease
The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20–30%. About 2–3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits. Population-based studies provide better estimates of the prevalence of NAFLD as compared to autoptic and clinical studies, but few such studies have been performed to date. The diagnosis of NAFLD in population studies is usually obtained by ultrasonography, which is known to underestimate the prevalence of fatty liver. The Dallas Heart Study and the Dionysos Study reported that 30% of the adults in the USA and 25% in Italy have NAFLD. In these studies, 79% and 55% of patients with NAFLD had normal aminotransferase levels, showing that liver enzymes are not surrogate markers of NAFLD in the general population. Noninvasive markers such as the fatty liver index obtained from the Dionysos Study may be useful to screen for NAFLD in the general population. The most important risk factors for NAFLD are male gender, age, obesity, insulin resistance and the cardiometabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80–90% in obese adults, 30–50% in patients with diabetes and up to 90% in patients with hyperlipidemia. The prevalence of NAFLD among children is 3–10%, rising up to 40–70% among obese children. Moreover, pediatric NAFLD increased from about 3% a decade ago to 5% today, with a male-to-female ratio of 2:1. The incidence and natural history of NAFLD are still not well defined, but it is recognized that the majority of individuals with NAFLD do not develop NASH. The incidence of NAFLD is probably increasing in Western countries, strictly linked to lifestyle habits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of NAFLD among normal-weight children is 3–10%, rising up to 40–70% among obese children”
From Lack of Exercise Is a Major Cause of Chronic Diseases (2012) · cites this paper as [33]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352 · cited 1×
“In the literature, many competing definitions of the MS are available. The definition recently put forth by the International Federation for the Study of Diabetes (IDF) [”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“It is important to note that this prevalence is partly dependent upon the method used to diagnose FL, the method used to assess alcohol intake and the cutoff point used to exclude ‘relevant’ alcohol intake, see table 2 , with respective references [ , , , , , , , , , , , , , , , , , , , , , ,”
MethodNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“] and 15p in Asian countries [ , , , , , , , , , ,”
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“We suggest to expand the number of prospective cohort studies in the general population, even if they are more expensive and difficult to handle, because they give more reliable results about the burden of disease attributable to NAFLD. The most simple, noninvasive and practical method for diagnosing FL in population…”
BackgroundSelf-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Population and clinical studies have increasingly shown that most cases of NAFLD are associated with the metabolic syndrome (MS), so that NAFLD is presently considered the hepatic manifestation of MS [”
BackgroundNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Definition and Classification of Non-Alcoholic Fatty Liver DiseaseNon-alcoholic fatty liver disease (NAFLD) is operationally defined as fatty liver (FL), i.e. an accumulation of lipids inside the hepatocytes exceeding 5p of the weight of the liver, without hepatitis B virus or hepatitis C virus infection and in the ab…”
BackgroundIndependent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610 · cited 1×
“A recent study showed that 27p of US adults have raised levels of liver enzymes and that 79p of these values cannot be explained by the most common causes of liver disease [ , , , , , , , ,”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568 · cited 1×
“While steatosis is usually associated with a benign prognosis, steatohepatitis and fibrosis may progress to cirrhosis and possibly hepatocarcinoma.During the last decade, the number of studies on NAFLD has grown exponentially, and new concepts have been acquired by the scientific community. We now know that NAFLD is o…”
Background
Research works printed but not linked: 7
- 10.1097%2f00005176-200001000-00017 · doi:10.1097/00005176-200001000-00017 · Paper page
- 10.1016%2fs1590-8658%2802%2980194-3 · DOI
- 10.1111%2fj.1572-0241.2001.04052.x · doi:10.1111/j.1572-0241.2001.04052.x · Paper page
- 10.1016%2fs0168-8278%2801%2900094-0 · DOI · Paper page
- 10.1111%2fj.1572-0241.1999.01451.x · doi:10.1111/j.1572-0241.1999.01451.x · Paper page
- 10.3109%2f00365527709181339 · DOI · Paper page
- 10.1053%2fgast.2001.25540 · DOI · Paper page
Cited by
Items 701–800 of 1,000
Perception of Non-Alcoholic Fatty Liver Disease: Real-Life Experience From Pakistan
Butt, N., Khan, M. A., Rai, L., Channa, R. H., Khemani, H., & Abbasi, A. (2021) · Cureus · doi:10.7759/cureus.16029 · Cited by 9
“79 years; this relatively young age is consistent with the obesity pandemic that is now affecting an ever younger populace and is being reported universally [4,14,23,24].”
BackgroundCan alanine aminotransferase measured in early pregnancy predict macrosomia?
Bulut, A. N., Ceyhan, V., & Dolanbay, M. (2022) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2022.2039905 · Cited by 7
“The prevalence in western countries has been reported as 20–30% (Bellentani et al. 2010).”
BackgroundZhou, Z., Tang, S., Zhou, Y., Luo, H.-S., & Liu, X. (2010) · Saudi Medical Journal · doi:10.15537/1658-3175.5143 · Cited by 9
Nonalcoholic Fatty Liver Disease
Lackner, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-42873-6.00012-3 · Cited by 9
Bai, J., Lei, P., Zhao, C., Wang, Y., Yan, D., & Yang, S. (2015) · Toxicology Reports · doi:10.1016/j.toxrep.2015.12.005 · Cited by 7
NUTRITIONAL STATUS, DIET AND NON-ALCOHOLIC FATTY LIVER DISEASE IN ELDERS.
Portela, C. L. D. M., Sampaio, H. A. D. C., de Melo, M. L. P., Carioca, A. A. F., Pinto, F. J. M., & Arruda, S. P. M. (2015) · PubMed · doi:10.3305/nh.2015.32.5.9674 · Cited by 7
Santhoshakumari, T. M. J. (2017) · IOSR Journal of Dental and Medical Sciences · doi:10.9790/0853-1601123337 · Cited by 7
Effect of a short-term physical activity intervention on liver fat content in obese children
Kang, D., Park, J., Lee, M. K., Kim, Y., Kong, I. D., Chung, C. H., Lee, Y., & Jeon, J. Y. (2017) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2017-0406 · Cited by 7
Lodhi, M., Amin, J. P., & Eswaran, S. L. (2018) · Clinical Liver Disease · doi:10.1002/cld.669 · Cited by 7
Bharath, R., Rajalakshmi, P., & Mateen, M. A. (2018) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2018.03.008 · Cited by 8
“If NAFLD is untreated, it may progress into chronic 4 liver diseases such as fibrosis, cirrhosis, hepatocellular carcinoma, liver cancer, 5 etc [2], [3].”
BackgroundCardiac Glycosides and Oxidative Stress in Liver Cancer
Çetin-Atalay, R., & Durmaz, İ. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-803951-9.00005-7 · Cited by 7
Nonalcoholic fatty liver disease in patients with type 2 diabetes
Petunina, N. A., & Эдуардовна, Т. М. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-4-92-95 · Cited by 8
Taketani, H., Nishikawa, T., Nakajima, H., Kodo, K., Sugimoto, S., Aoi, W., Horike, S., Meguro‐Horike, M., Ishiba, H., Seko, Y., et al. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s214093 · Cited by 9
Work up of fatty liver by primary care physicians, review
Rikhi, R. R., Singh, T., & Esfeh, J. M. (2020) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2020.01.001 · Cited by 7
Thiagarajan, P., Chalmers, J., Ban, L., Grindlay, D. J. C., & Aithal, G. P. (2020) · World Journal of Meta-Analysis · doi:10.13105/wjma.v8.i1.4 · Cited by 7
Fan, S., Zhang, H., Wang, Y., Zhao, Y., Luo, L., Wang, H., Chen, G., Xing, L., Zheng, P., & Huang, C. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00445 · Cited by 7
Arıkan, D., Önmez, A., Aksu, E., & Taşdemir, N. (2022) · African Health Sciences · doi:10.4314/ahs.v22i1.75 · Cited by 7
Kawamura, Y., Saitoh, S., Arase, Y., Ikeda, K., Fukushima, T., Hara, T., Seko, Y., Hosaka, T., Kobayashi, M., Sezaki, H., et al. (2013) · Hepatology International · doi:10.1007/s12072-012-9419-7 · Cited by 7
Dietary Intervention in Non-Alcoholic Fatty Liver Disease
Abenavoli, L., & Milić, N. (2013) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2012.11.019 · Cited by 7
Antypas, A., Austin, A. S., Awad, S., Hughes, D., & IDRIS, I. R. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04878-6 · Cited by 7
Zhong, Z., Xu, M., Luo, X., & Tan, J. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04497-4 · Cited by 8
“Furthermore, NAFLD is often underdiagnosed, especially in the early stages when the disease is asymptomatic, leading to delays in treatment and a higher risk of progression to more severe forms of liver disease [11].”
Childhood Obesity: A Multisystem Challenge Linking Hypertension, NAFLD, and Sleep Apnea
Montagnana, M., Danese, E., Bonafini, S., & Fava, C. (2026) · Medical Sciences · doi:10.3390/medsci14010070 · Cited by 7
“Reported prevalence rates vary widely according to the characteristics of the population studied and the accuracy of the diagnostic test [65,66].”
Animal Models of Disease for Future Toxicity Predictions
Morgan, S. J., & Elangbam, C. S. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch18 · Cited by 8
Sanchez-Torrijos, Y. M., Herrojo, J. A., Pérez-Palacios, D., Gallego‐Durán, R., & Romero‐Gómez, M. (2019) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2019.6088/2018 · Cited by 6
Mohamed, A., Isa, H. M. A., Ali, M. S., Dadi, A., & Kadhim, Z. (2021) · Oman Medical Journal · doi:10.5001/omj.2022.53 · Cited by 6
Changing the cause of liver cirrhosis from hepatitis B virus to fatty liver in Iranian patients.
Hatami, B., Ashtari, S., Sharifian, A., Seraji, H. R., Khalili, E., Hatami, Y., & Zali, M. R. (2017) · Gastroenterology and hepatology from bed to bench. · Cited by 6
Lemdani, K., Salmon, H., Gahoual, R., Bessodes, M., Scherman, D., Houzé, P., Séguin, J., & Mignet, N. (2018) · Nanoscale · doi:10.1039/c8nr04163f · Cited by 6
Wang, B., Wang, J., Du, W., & Shang, S. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2707199 · Cited by 6
“NAFLD has become one of the most common liver diseases globally and has gradually attracted attention [3].”
BackgroundSalgado‐Álvarez, G. A., Gálvez, S. M. P., Mora, U. G., Cano-Contreras, A. D., Durán-Rosas, C., Priego-Parra, B. A., Triana‐Romero, A., Amieva‐Balmori, M., Dietlen, F. B. R., Vázquez, S., et al. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i8.1633 · Cited by 6
Immune and metabolic cross-links in the pathogenesis of comorbid non-alcoholic fatty liver disease
Kotlyarov, S. N. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i4.597 · Cited by 6
Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients
Uhanova, J., Minuk, G. Y., Ficher, F. L., & Chandok, N. (2016) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2016/6420408 · Cited by 6
“Thus, as the prevalence of diabetes and obesity continues to increase in developed nations, there has been an accompanying increase in the prevalence of NAFLD such that the estimated prevalence of NAFLD in North America is approaching 30% of the adult population [2–4].”
Insulin Resistance in Nonalcoholic Fatty Liver Disease: Experience from Bangladesh
Azam, G., Alam, S., Hasan, S. N., Alam, S. M. N. E., Kabir, J., & Alam, A. K. (2016) · Bangladesh Critical Care Journal · doi:10.3329/bccj.v4i2.30022 · Cited by 7
A Case Report of Adolescent Nonalcoholic Fatty Liver Disease (NAFLD) with Obesity
Kang, K., Lee, M.-S., Jung, Y., Choi, A.-R., Han, D.-G., Kang, A.-H., Song, W.-S., Lee, H.-C., & Um, G.-H. (2016) · The Journal of Internal Korean Medicine · doi:10.22246/jikm.2016.37.5.726 · Cited by 6
“Journal of Korean oriental internal medicine 2010;31(2):331-45.”
Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD
Patton, A., Church, T., Wilson, C. L., Thuma, J. R., Goetz, D. J., Berryman, D. E., List, E. O., Schwartz, F., & McCall, K. D. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0078 · Cited by 7
Zubair, R., Mirza, M. R., Iftikhar, J., & Saeed, N. (2018) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.345.15102 · Cited by 6
Park, S., Han, A. L., Kim, N.-H., & Shin, S. (2018) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000515 · Cited by 6
Bandaru, V. C. S. S., Chaudhuri, J. R., Lalitha, P., Reddy, S. N., Misra, P. K., Balaraju, B., & Mridula, K. R. (2019) · The Egyptian Journal of Internal Medicine · doi:10.4103/ejim.ejim_76_18 · Cited by 6
Lăpădat, A. M., Florescu, L. M., Manea, N. C., Gheonea, D. I., Pirici, D. N., Tudoraşcu, D. R., Ene, R., & Gheonea, I. A. (2020) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.61.1.08 · Cited by 6
Sirinawasatien, A., & Techasirioangkun, T. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/8814135 · Cited by 6
“The prevalence of steatosis in HCVinfected patients has been reported to be approximately 50% [4], much higher than that of the general population (20-30%) [5, 6].”
BackgroundLiu, L., Zhou, Y., Dai, D., Xia, H., Zhao, K. F., & Zhang, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5649575 · Cited by 9
Nobakht, H., Mahmoudi, T., Rezamand, G., Tabaeian, S. P., Jeddi, G., Asadi, A., Farahani, H., Dabiri, R., Mansour‐Ghanaei, F., Kaboli, S. A., et al. (2022) · Laboratory Medicine · doi:10.1093/labmed/lmac039 · Cited by 6
Salehi‐Sahlabadi, A., Kord‐Varkaneh, H., Bozkurt, B. K., Seraj, S. S., Alavian, S. M., & Hekmatdoost, A. (2022) · Phytotherapy Research · doi:10.1002/ptr.7553 · Cited by 6
Valoración de la grasa hepática y pancreática como biomarcadores de imagen en el síndrome metabólico
Ballester-Vallés, C., Flores-Méndez, J., Delgado‐Moraleda, J. J., Martín-Portugués, A. B., Merino-Torres, J. F., Fornés, V., & Martí‐Bonmatí, L. (2019) · Radiología · doi:10.1016/j.rx.2019.05.010 · Cited by 6
Mahmoudi, T., Ghorbani, D., Rezamand, G., Dehestan, N., Jeddi, G., Asadi, A., Nobakht, H., Dabiri, R., Farahani, H., Tabaeian, S. P., et al. (2023) · Personalized Medicine · doi:10.2217/pme-2022-0100 · Cited by 6
Ma, Y., Harris, J., Li, P., Jiang, C., Sun, H., & Cao, H. (2024) · Non-Coding RNA · doi:10.3390/ncrna10030034 · Cited by 7
“In the past two decades, non-alcoholic fatty liver disease (NAFLD) has become a major public health threat in the US and worldwide, affecting 30% of the general population [1,2].”
BackgroundHan, J., Chen, J., Hu, H., Song, Y., Chen, M., Zhao, D., Shan, W., Zhang, Q., & Xu, L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157519 · Cited by 5
Convergent Metabolic Pathways in MASH Therapeutics: An AMPK ‐Centric Analysis
Choi, S., Jung, J., Seo, Y., Song, S., Ham, J., Chung, H., Ramadan, Y., & Choi, K. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71023 · Cited by 6
“The pathogenesis of MASH is closely associated with systemic metabolic factors, including insulin resistance, elevated fatty acids and pro-inflammatory signals [12].”
Plaikner, M., Kremser, C., Zoller, H., Jaschke, W. R., Steurer, M., Viveiros, A., & Henninger, B. (2020) · European Radiology · doi:10.1007/s00330-020-07010-5 · Cited by 5
Mahmoudi, T., Nouri, S., Zarei, F., Najafabadi, Z. N., Sanei, M., Sayedsalehi, S., Rezamand, G., Asadi, A., Dabiri, R., Nobakht, H., et al. (2023) · PubMed Central · doi:10.20945/2359-4292-2023-0017 · Cited by 5
Doycheva, I., Cox, K., Haseeb, A., & Adler, D. G. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3051-4 · Cited by 5
Kim, M. K., Rho, Y., Park, R., Jung, J., Hwang, G., Seo, Y. K., Seo, J. H., Heo, Y., Ha, T. K., & Ha, E. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.02.011 · Cited by 6
Adnan, M., & Pramaningtyas, M. D. (2022) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2022.118275 · Cited by 5
“NAFLD can be defined as the condition of steatosis of the liver that results from the accumulation of fat in the liver that is not caused by alcohol consumption and other secondary causes of liver steatosis [2].”
BackgroundShaikh, A., Pedra, G., Ruiz‐Casas, L., Franks, B., Dhillon, H. S., Fernandes, J. D. D. R., Mangla, K. K., Augusto, M., Romero‐Gómez, M., & Schattenberg, J. M. (2023) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2023.10.005 · Cited by 5
Zakeri, A., & Karamat-Panah, S. (2018) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20180747 · Cited by 5
Tan, C.-H., Al-Kalifah, N., Lee, W., Ser, K., Lee, Y.-C., & Chen, J. (2018) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2018.04.010 · Cited by 5
Molecular alterations induced by fructose and its impact on metabolic diseases
Loza-Medrano, S. S., Baiza-Gutman, L. A., Ibáñez-Hernández, M. Á., Cruz, M., & Díaz-Flores, M. (2019) · PubMed · Cited by 15
Hepatic and pancreatic fat as imaging biomarkers of metabolic syndrome
Ballester-Vallés, C., Flores-Méndez, J., Delgado‐Moraleda, J. J., Martín-Portugués, A. B., Merino-Torres, J. F., Fornés, V., & Martí‐Bonmatí, L. (2020) · Radiología (English Edition) · doi:10.1016/j.rxeng.2019.10.005 · Cited by 6
Non-alcoholic fatty liver disease and transient elastography
Mikolašević, I., Lukić, A., Jurić, T., Klapan, M., Madzar, P., Krolo, N., Kolovrat, D., Jurica, I., Kedmenec, I., Kihas, D., et al. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00014 · Cited by 6
“One-third of patients with NAFLD have MetS and 90% of NAFLD patients have at least one component of MetS [4-12].”
BackgroundChang, C.-H., Chen, S., Geng, J., Wu, D., Huang, J., & Wu, P.-Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11101033 · Cited by 5
“Previous studies have shown that nonalcoholic fatty liver disease (NAFLD) is associated with the inflammatory status of the liver, and that this can lead to a cascade that affects the lungs over the long term [43,44].”
BackgroundVibration‐controlled transient elastography for noninvasive evaluation of liver steatosis
Pearson, A., Dujardin, P., d’Altéroche, L., Patat, F., Scotto, B., Dujardin, F., Bastard, C., Miette, V., Sandrin, L., & Réméniéras, J.-P. (2022) · Medical Physics · doi:10.1002/mp.15484 · Cited by 5
“(3) Our algorithm estimated μVoigt and ηVoigt, and μFibroscan was extracted from the data.”
Li, L., Xiong, Y., Cao, W., Chen, Z., He, L., Tong, M., Zhang, L., & Wu, M. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.02.051 · Cited by 5
RetractedBreit, H., Vosshenrich, J., Heye, T. J., Gehweiler, J., Winkel, D. J., Potthast, S., Merkle, E. M., & Boll, D. T. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-884 · Cited by 8
“Subsumed disease entities include non-alcoholic fatty liver disease (NAFLD) with a current prevalence of about 20–30% in western countries (2), alcoholic fatty liver disease (3) as well as viral hepatitis (4).”
Abenavoli, L., Peta, V., & Milić, N. (2015) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30809-9 · Cited by 5
Early warning of liver disease in diabetics
Arab, J. P., Ramírez, C., & Arrese, M. A. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31646-1 · Cited by 5
Ren, T., Chen, Q., & Zhu, C. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.04.026 · Cited by 5
An, Y.-M., Jun, D. W., & Lee, S. M. (2015) · Clinical Nutrition Research · doi:10.7762/cnr.2015.4.4.250 · Cited by 5
Yin, X., Chi, W., Zhang, L., Su, Y.-X., Zhang, Z., & Xue, C. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13687 · Cited by 5
Yang, H., Zhang, T., Rayamajhi, S., Thapa, A., Du, W., Meng, G., Zhang, Q. H., Liu, L., Wu, H., Gu, Y., et al. (2022) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2022.2050997 · Cited by 4
“2019), both of which play an important role in the pathogenesis of NAFLD (Bellentani et al. 2010).”
BackgroundChanging trends in the etiology of liver transplantation in Turkiye: A multicenter study
Akarsu, M., Dolu, S., Harputluoglu, M. M. M., Yılmaz, S., Akyıldız, M., Gençdal, G., Polat, K. Y., Dinçer, D., Adanır, H., Turan, İ., et al. (2024) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2023.2023.0010 · Cited by 4
Armisen, J., Flor, A. W., Eriksson, J., Nelander, K., Bhattacharya, C. S., Sunnåker, M., Carter, D., Trebski, M., Gårdmark, E., Aurell, M., et al. (2025) · Liver International · doi:10.1111/liv.70406 · Cited by 4
Annunziato, R. A., Rubes, M., Davis, C., Rose, S., & Arnon, R. (2014) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2014.07.001 · Cited by 4
Tan, H., Xu, L., Liu, X., Si, S., Sun, Y., Liu, L., Zhou, W., & Yang, Z. (2015) · PubMed Central · Cited by 4
Chronic Liver Failure and Hepatic Cirrhosis
Grinspan, L. T., & Verna, E. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-64298-7_2 · Cited by 4
Özsoy, B., Küçükgül, A., Özsoy, Ş. Y., & Yumuşak, N. (2017) · Harran Üniversitesi Veteriner Fakültesi Dergisi · doi:10.31196/huvfd.384398 · Cited by 4
Rasdiana, R., Hp, F., Akil, F., Parewangi, M. L., Kasim, H., Sanusi, H. D., Syahriani, F., Bakri, S., Rasyid, H., & Seweng, A. (2020) · Global Journal of Health Science · doi:10.5539/gjhs.v13n1p103 · Cited by 4
“The highest prevalence of NAFLD in western countries is found in obese individuals ranging from 80% -90% (Bellentani et al., 2010).”
Ethyl pyruvate supplemented in drinking water ameliorates experimental nonalcoholic steatohepatitis
Sun, X., Zhu, S., Dong, X., Strand-Amundsen, R. J., Tønnessen, T. I., & Yang, R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111392 · Cited by 4
Jamialahmadi, T., Nematy, M., Abdalla, M. A., Jangjoo, A., Goshayeshi, L., Kroh, M., Moallem, S. A., Abbasifard, M., Sathyapalan, T., & Sahebkar, A. (2022) · Journal of Nutrition and Metabolism · doi:10.1155/2022/7319742 · Cited by 4
“Worldwide, along with a rapid rise in the number of patients with obesity, nonalcoholic fatty liver disease (NAFLD) prevalence is also increasing, affecting 20–30% of the population across the world [1].”
Nutritional Intake and the Risk for Non-alcoholic Fatty Liver Disease (NAFLD)
Bergheim, I., & Schattenberg, J. M. (2019) · MDPI eBooks · doi:10.3390/books978-3-03897-599-1 · Cited by 6
RESISTIN GENE POLYMORPHISM AND NONALCOHOLIC FATTY LIVER DISEASE RISK
Tabaeian, S. P., Mahmoudi, T., Rezamand, G., Nobakht, H., Dabiri, R., Farahani, H., Asadi, A., & Zali, M. R. (2022) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.202204000-86 · Cited by 4
Additional Potential Therapeutic Applications for Rice Bran Arabinoxylan Compound
Micalos, P. S., Pak, S. C., & Ooi, S. L. (2023) · Springer eBooks · doi:10.1007/978-981-19-5735-2_12 · Cited by 4
Kemaloglu, C. A., & Kemaloğlu, M. D. (2019) · Nepalese Heart Journal · doi:10.3126/njh.v16i1.23898 · Cited by 4
“Nepalese Heart Journal 2019; Vol 16(1), 39-45 widely accepted, convenient marker of atherosclerosis is carotid artery intima-media thickness (c-imt) which is significantly associated with prevalence and incidence of carotid plaques.”
BackgroundMethodInfluentialParry, I. (2013) · Journal of Metabolic Syndrome · doi:10.4172/2167-0943.1000118 · Cited by 6
Hepatocellular Carcinoma: Known and Emerging Risk Factors
Sciancalepore, D., Zingaro, M. T., Luglio, C. V., Sabbà, C., & Napoli, N. (2018) · Journal of Cancer Therapy · doi:10.4236/jct.2018.95037 · Cited by 4
“NAFLD is the most common hepatic disorder in developed countries, with a prevalence ranging from 6% to 35% [63]; moreover, it is considered the emerging leading cause of chronic liver disease, with an estimated incidence in Western countries (20% - 30%) higher than in Asia (5% - 18%) [64].”
BackgroundKohda, Y., Ueda, J., Azuma, R., Nakatani, Y., Murase, H., Matsui, K., Takezoe, Y., Nagata, E., Matsui, R., Tanaka, T., et al. (2019) · Fundamental Toxicological Sciences · doi:10.2131/fts.6.1 · Cited by 4
“The incidences of obesity and metabolic syndrome have increased globally, and NAFLD has become the most common liver disease, accelerating the need for countermeasures (Lazo and Clark, 2008; Argo and Caldwell , 2009; Bellentani and Marino, 2009; Bellentani et al., 2010).”
BackgroundDarand, M., Darabi, Z., Yari, Z., & Hekmatdoost, A. (2019) · Hepatitis Monthly · doi:10.5812/hepatmon.88283 · Cited by 4
Sonographic Features of the Liver Among Females With Type 2 Diabetes
Riestra‐Candelaria, B. L., Gonzalez-Rodriguez, L. A., Rodríguez-Mojica, W., Vázquez-Quiñones, L. E., & Jorge, J. C. (2019) · Journal of diagnostic medical sonography · doi:10.1177/8756479319834927 · Cited by 4
Serologic Biomarkers for Hepatic Fibrosis in Obese Children with Nonalcoholic Steatohepatitis
Joo, J. Y., Yoo, I. H., & Yang, H. R. (2024) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2024.27.4.236 · Cited by 4
“Accordingly, the prevalence of obesity-related complications, such as nonalcoholic fatty liver disease (NAFLD) and metabolic syndromes, is rapidly increasing [2,3].”
BackgroundFen, G., Ma, Y., Yu, C. I., & Duan, Q. (2025) · Gene · doi:10.1016/j.gene.2025.149419 · Cited by 5
Betzel, B., & Drenth, J. P. H. (2014) · BMC Medicine · doi:10.1186/s12916-014-0152-z · Cited by 3
“Similar to obesity, NAFLD has reached epidemic proportions with a prevalence of 20% to 30% in western populations [1].”
Zvyagintseva, T. D., & Glushchenko, S. V. (2016) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v15i1.20660 · Cited by 3
Hubungan Stadium Hipertensi dengan Derajat Perlemakan Menggunakan Indeks Hepatorenal Sonografi
Marina, D., Nugraha, H. G., Santiana, L., & Diyanti, L. N. (2017) · Global Medical & Health Communication (GMHC) · doi:10.29313/gmhc.v5i3.2175 · Cited by 3
CLINICAL PROFILE OF NAFLD PATIENTS AND ITS CORRELATION WITH METABOLIC SYNDROME
Nigam, P., Pandey, R. P., Pawar, M., & Indurkar, M. (2018) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2018/96 · Cited by 3
Dietary Interventions in Fatty Liver
Yari, Z., & Hekmatdoost, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814468-8.00020-x · Cited by 5
Paulino, B. C., Aquino, J. D. S., de Souza, E. L., Gomes, J. A. D. S., Lins, P. P., de Lima, T. A. S., Alves, E. M. D. S., & do Nascimento, E. (2019) · Journal of Food and Nutrition Research · doi:10.12691/jfnr-7-4-6 · Cited by 3
“The NAFLD is a disease associated with dietary fat intake independent of excess caloric consumption [37] and often associated with the most common clinical features of metabolic syndrome, such as central obesity, type 2 diabetes mellitus, dyslipidemia and arterial hypertension [38] reaching prevalence in the general p…”
BackgroundInfluence of omega-3 fatty acids and monounsaturated fats in liver diseases
Abdullah, Rehman, M. U., Khan, F., & Niaz, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816488-4.00013-9 · Cited by 3
Saki, K., Mansouri, V., Abdi, S., Fathi, M., Razzaghi, Z., & Haghazali, M. (2021) · Gastroenterology and hepatology from bed to bench. · Cited by 4
Zambrano‐Zaragoza, J. F., Vázquez‐Reyes, A., Durán‐Avelar, M. D. J., Gutiérrez‐Franco, J., Vibanco‐Pérez, N., Agraz‐Cibrián, J. M., Pérez‐Cambero, H., & Ayón‐Pérez, M. F. (2022) · Annals of Human Genetics · doi:10.1111/ahg.12466 · Cited by 3
“NALFD, around 70% of people with IR develop NALFD, and 50% of people with DM2 will go on to develop NALFD (Bellentani et al., 2010); nevertheless, the development of NALFD remains unclear (Ipsen et al.”
BackgroundMahabaleshwarkar, R., Liu, T., McKillop, I. H., & Spencer, M. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2021.0108 · Cited by 3
Chu, D., Bui, N.-L., & Le, N. H. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.06.024 · Cited by 3
Barazesh, M., Jalili, S., Akhzari, M., Faraji, F., & Khorramdin, E. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230417111247 · Cited by 3
Metadata
- Authors
- Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 28
- Issue
- 1
- Pages
- 155-161
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2036047239
- Cited by
- 1,026
- References
- 77
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 31 · 2023: 51 · 2022: 72 · 2021: 71 · 2020: 78 · 2019: 85 · 2018: 96 · 2017: 97 · 2016: 89 · 2015: 84 · 2014: 71 · 2013: 81 · 2012: 48
- FWCI
- 40.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, prevalence, nonalcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, obesity, insulin resistance, metabolic syndrome, fatty liver index, NAFLD screening, pediatric NAFLD, incidence, lifestyle, transaminases
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Humans, Italy, Male, Middle Aged, Risk Factors, United States, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.